Use of rituximab in idiopathic retroperitoneal fibrosis

BACKGROUND: Retroperitoneal fibrosis (RPF) is characterized by the proliferation of fibrous tissue in the retroperitoneum. The majority of RPF cases are due to idiopathic or IgG4-related disease. Recent studies on IgG4-related disease have shown rituximab to be an effective treatment. The current fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyeva, Veronika, Alabsi, Hatim, Seidman, Michael A., Paterson, Ryan, Kur, Jason, Chen, Luke Y. C., Chang, Silvia D., Carruthers, Mollie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409628/
https://www.ncbi.nlm.nih.gov/pubmed/32775962
http://dx.doi.org/10.1186/s41927-020-00140-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409628/
https://www.ncbi.nlm.nih.gov/pubmed/32775962
http://dx.doi.org/10.1186/s41927-020-00140-9

Ejemplares similares